vallos®
A new allograft that sets the pace for regeneration
Geistlich understands that in certain clinical situations, rapid turnover of new bone is important. That‘s why we‘re bringing you vallos® demineralized allogeneic granules and fibers that allow you to set the pace for treatment success.
With vallos® you can expect:
- Consistent product quality1
- Verified osteoinductive potential in every lot1
- Vital bone after 18-20 weeks2
References:
- Compiled DCI Osteoinductivity Validation Summary_2020. (data on file)
- Robert A Wood & Brian L Mealey: J Periodontol. 2012 Mar;83(3):329-36. (Clinical Study)
- Piattelli M et al.: Int J Oral Maxillofac Implants 1999; 14 (6), 835-40. (Clinical Study).
- Sartori S et al.: Clin Oral Implants Res 2003; 14 (3), 369-72. (Clinical Study).
- Maiorana C et al.: Int J Periodontics Restorative Dent 2005; 25 (1), 19-25. (Clinical Study).
- Orsini G et al.: Oral Dis 2007; 13 (6), 586-93. (Clinical Study).
- Lindgren C et al.: Int J Oral Maxillofac Implants 2009; 24 (6), 1093-100. (Clinical Study).
- Mordenfeld A et al.: Clin Oral Implants Res 2010; 21 (9), 961-70. (Clinical Study).
- Serrano CA et al.: Implant Dent. 2018 Aug; 27(4):467-473. (Clinical Study).
- NCBI Pubmed, Month Year, Search term “Bio-Oss” (1208 hits) (Market research).
- Berglundh T & Lindhe J: Clin Oral Implants Res 1997; 8 (2), 117-24. (Preclincal Study).
- Weibrich G et al.: Mund Kiefer Gesichtschir 2000; 4 (3), 148-52. (Preclincal Study).
- Degidi M et al.: Oral Dis 2006; 12 (5), 469-75. (Clinical Study).
- Galindo-Moreno P et al.: Clin Oral Implants Res 2010; 21 (2), 221-7. (Clinical Study).
- Data on file, Geistlich Pharma AG, Switzerland
vallos® allograft
vallos® Product Range
01/05
vallos® and vallos®f
- Proven regenerative capacity by exhibiting all five elements of bone formation1
- Delivers osteogenic cells when hydrated with bone marrow aspirate3
- Promotes structural integrity that supports the integration of implants
- Second surgical site is not required
- 5-year shelf life
In addition to the benefits above, vallos®f fibers also provide:
- Enhanced handling characteristics to provide precise graft placement1
- 4X higher osteoinductive potential than particulate DBM4
vallos™ is available as a standalone or with Geistlich vallomix™, which conveniently co-packs vallos™ and Geistlich Bio-Oss®. Together these proven products bring optimal consistency and performance in demanding clinical situations.1-16
References:
- Data on file, DCI Donor Services Tissue Bank
- Robert A Wood & Brian L Mealey: J Periodontol. 2012 Mar;83(3):329-36. (Clinical Study
- Muschler GF. J Bone Joint Surg Am. 1997; 79, 1699-1709
- Martin GJ, et. Al. Spine, 1999, 24, 637-645
- Piattelli M et al.: Int J Oral Maxillofac Implants 1999; 14 (6), 835-40. (Clinical Study)
- Sartori S et al.: Clin Oral Implants Res 2003; 14 (3), 369-72. (Clinical Study)
- Maiorana C et al.: Int J Periodontics Restorative Dent 2005; 25 (1), 19-25. (Clinical Study)
- Orsini G et al.: Oral Dis 2007; 13 (6), 586-93. (Clinical Study)
- Lindgren C et al.: Int J Oral Maxillofac Implants 2009; 24 (6), 1093-100. (Clinical Study)
- Mordenfeld A et al.: Clin Oral Implants Res 2010; 21 (9), 961-70. (Clinical Study)
- Serrano CA et al.: Implant Dent. 2018 Aug; 27(4):467-473. (Clinical Study)
- NCBI Pubmed, Month Year, Search term “Bio-Oss” (1208 hits) (Market research)
- Berglundh T & Lindhe J: Clin Oral Implants Res 1997; 8 (2), 117-24. (Preclincal Study)
- Weibrich G et al.: Mund Kiefer Gesichtschir 2000; 4 (3), 148-52. (Preclincal Study)
- Degidi M et al.: Oral Dis 2006; 12 (5), 469-75. (Clinical Study)
- Galindo-Moreno P et al.: Clin Oral Implants Res 2010; 21 (2), 221-7. (Clinical Study)
CAUTION: Federal law restricts these devices to sale by or on the order of a dentist or physician.
